Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2025 U.S. Biopharma Recap

The second quarter was another rollercoaster period for biopharma, opening with “Liberation Day” and closing amid mounting macro and geopolitical uncertainty. While the sector continues to lag broader healthcare, investor sentiment showed early signs of stabilization. The XBI and NBI posted mid-single-digit gains, trimming YTD losses to ~9% and ~2.6%, respectively.

Financing activity remains constrained with total capital raised across privates and publics down 53% YoY. April marked a low for activity and Q2 marked the first quarter since the Great Financial Crisis without a single IPO. As the IPO window remains unclear, “crossover” activity also thinned with only seven deals announced and average size dipping below $100 million for the first time since Q4 2020. Follow-ons and structured financings (PIPEs/RDs) were hit hardest with only 28 deals announced, the lowest since Q1 2022, as activity remained concentrated around key clinical and regulatory milestones.

Reverse merger activity also stalled as many cash-rich shells increasingly pursue shareholder returns via take-privates or capital distributions following strategic reviews. On the BD front, M&A activity shifted back to public targets with Blueprint/Sanofi, Springworks/Merck KgAA, and Verve/Lilly each topping $1 billion in upfronts, demonstrating that buyers are still willing to pay for innovation and derisked pipelines.

Our midyear investor survey shows a measured but constructive outlook for the remainder of 2025, with focus firmly on mid-/late-stage clinical names and a watchful eye on interest rates and MFN implementation.

William Blair’s biopharma team shares additional perspectives on what lies ahead for the sector.

Complete the form below to download a copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Monthly Macro: Energy Efficiency, Scarcity, and the Next Wave of Demand

    William Blair macro analyst Richard de Chazal and energy analyst Neal Dingmann discuss how rapid technological advances, shrinking inventories, and relentless demand—especially for natural gas—are reshaping the energy sector, driving new strategies and investment opportunities for the years ahead.

    Listen to the podcast
  • Sheridan Capital Partners Has Acquired Currier Plastics

    William Blair acted as exclusive financial advisor to Sheridan Capital Partners in connection with its acquisition of Currier Plastics.

    Read more
  • Economics Weekly: Fed Independence, Fiscal Dominance, and How Government Debt Problems Manifest

    In this Economics Weekly, Richard de Chazal discuss the early signs of a shift toward fiscal dominance and the gradual erosion of Federal Reserve independence—developments that carry significant implications for both the economy and the investment landscape.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures